Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy
Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Summary
The objective of the study is to evaluate the predictive value of TMPRSS2-ERG gene fusion and PTEN in patients with high risk prostate cancer treated with first line LHRH agonist after biochemical failure.
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
208
Start Date
2016-03
Completion Date
2027-03
Last Updated
2024-12-04
Healthy Volunteers
No
Conditions
Locations (9)
CIUSSS du Saguenay-Lac-St-Jean/CSSS de Chicoutimi
Chicoutimi, Quebec, Canada
CISSS de la Montérégie-Centre - Hôpital Charles-LeMoyne
Greenfield Park, Quebec, Canada
CISSS de Laval - Hôpital de la Cité-de-la-santé de Laval
Laval, Quebec, Canada
CIUSSS de l'Est-de-l'Île-de-Montréal - Hôpital Maisonneuve-Rosemont
Montreal, Quebec, Canada
Jewish General Hospital, McGill University
Montreal, Quebec, Canada
MUHC - Cedars Cancer Center
Montreal, Quebec, Canada
CHU - L'Hôtel-Dieu de Québec
Québec, Quebec, Canada
CIUSSS de l'Estrie - Hôpital Fleurimont
Sherbrooke, Quebec, Canada
CIUSSS de la Mauricie-et-du-centre-du Quebec - Centre hospitalier régional de Trois-Rivières
Trois-Rivières, Quebec, Canada